Released May 6, 2019, before the open
10-Q filed May 6, 2019, 36 days after period end · 0001144204-19-023895
Q1 2019 · 10-Q
Revenue$10.44M$10.44M +129.3% vs Q1 2018−61.4% vs Q4 2018
Net Income-$7.26M-$7.26M N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.50-$0.50 N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$5,534,000N/M
Operating Cash Flow-$7,276,000N/M
Free Cash Flowderived-$7,446,000N/M
Margins · derived
Operating margin-53.0%+60.1 pt vs Q1 2018
Net margin-69.6%+89.4 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $10.44M | $4.55M | $2.89M | $679.00K |
| Net Income | -$7.26M | -$7.24M | -$59.15M | -$8.60M |
| EPS Diluted | -$0.50 | -$0.50 | -$0.48 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR